Novo Nordisk | NVO - Operating Expenses


Novo Nordisk reported DKK6.5B in Operating Expenses for its fiscal quarter ending in June of 2025.





Operating Expenses Change Date
ANI Pharmaceuticals USD 505.82M 309.62M Sep/2025
Aurora Cannabis CAD 146.03M 27.79M Sep/2025
Bausch Health Companies USD 2.08B 113M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Canopy Growth CAD 80.99M 8.64M Sep/2025
Corcept Therapeutics USD 197.42M 29.66M Sep/2025
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Merck USD 10.16B 558M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Novartis USD 9.86B 115M Sep/2025
Novo Nordisk DKK 46.76B 3.99B Dec/2025
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Phibro Animal Health USD 332.36M 20.68M Dec/2025
Prestige Brands USD 200.95M 6.51M Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025
Zoetis USD 1.55B 3.85B Dec/2025